| Species |
Human |
| Protein Construction |
MUC1 Isoform Y (Ser24-Gly158)_x000D_
Accession # P15941-7 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
41.38 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 55-65 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
MUC1, the transmembrane glycoprotein Mucin 1, is usually found to be overexpressed in a variety of epithelial cancers playing an important role in disease progression. MUC1 isoforms such as MUC1/Y, which lacks the entire variable number of tandem repeat region, are involved in oncogenic processes by enhancing tumour initiation. MUC1/Y is therefore considered a promising target for the identification and treatment of epithelial cancers. |
| Synonyms |
MUC1/Y; MUC1; MUC-1; Mucin-1; Mucin1; CA 15-3; Episialin; H23AG; KL-6; PEMT; PUM; PEM; EMA; CD227; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
